Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038761 | 0.78 | MAPT (0.41) | PDE4APDE4CPDE4DPDE4BTP53 | |
| SCHEMBL23809320 | 0.74 | ALDH1A1 (0.49) | PDE4APDE4CPDE4DPDE4BTP53 | |
| SCHEMBL12026641 | 0.74 | MET (0.49) | PDE4APDE4CPDE4DPDE4BTP53 | |
| SCHEMBL6180957 | 0.73 | PDE4A (0.49) | PDE4APDE4CPDE4DPDE4B | |
| SCHEMBL6181290 | 0.73 | PDE4A (0.50) | PDE4APDE4CPDE4DPDE4BAKR1C3 | |
| SCHEMBL7448426 | 0.73 | PDE4A (0.56) | PDE4APDE4CPDE4DPDE4BNR3C1 | |
| SCHEMBL7434938 | 0.72 | PDE4A (0.56) | PDE4APDE4CPDE4DPDE4BAKR1C3 | |
| SCHEMBL6183127 | 0.72 | PDE4A (0.46) | PDE4APDE4CPDE4DPDE4BAKR1C3 | |
| SCHEMBL4040391 | 0.72 | PDE4A (0.54) | PDE4APDE4CPDE4DPDE4B | |
| SCHEMBL1223701 | 0.70 | PDE4A (0.47) | PDE4APDE4CPDE4DPDE4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601354-A4 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2009-08-12 | — | — | EP | claimed |
| EP-1601354-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2005017126-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2013036574-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2013-03-14 | — | — | WO | disclosed |
| EP-1487797-B1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-7144896-B2 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-11-03 | — | — | US | disclosed |
| EP-1487797-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078397-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4C 3/4885PDE4D 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.